OpenLB
Open Library of Bioscience
Advanced Search
Medical review (2021)
Feb, 2024;4 (1): 5-30.

Nanotechnology-based delivery systems to overcome drug resistance in cancer.

Harsh Patel, Jiaxin Li, Letao Bo, Riddhi Mehta, Charles R Ashby, Shanzhi Wang, Wei Cai, Zhe-Sheng Chen
Author Information
  1. Harsh Patel: College of Pharmacy and Health Sciences, St. John's University, New York, NY, USA. ORCID
  2. Jiaxin Li: College of Pharmacy and Health Sciences, St. John's University, New York, NY, USA.
  3. Letao Bo: College of Pharmacy and Health Sciences, St. John's University, New York, NY, USA.
  4. Riddhi Mehta: St. John's College of Liberal Arts and Sciences, St. John's University, New York, NY, USA.
  5. Charles R Ashby: College of Pharmacy and Health Sciences, St. John's University, New York, NY, USA.
  6. Shanzhi Wang: College of Pharmacy and Health Sciences, St. John's University, New York, NY, USA.
  7. Wei Cai: School of Pharmaceutical Sciences, Hunan University of Medicine, Huaihua, Hunan Province, China. ORCID
  8. Zhe-Sheng Chen: College of Pharmacy and Health Sciences, St. John's University, New York, NY, USA. ORCID
PMID: 38515777 DOI: 10.1515/mr-2023-0058

Abstract

Cancer nanomedicine is defined as the application of nanotechnology and nanomaterials for the formulation of cancer therapeutics that can overcome the impediments and restrictions of traditional chemotherapeutics. Multidrug resistance (MDR) in cancer cells can be defined as a decrease or abrogation in the efficacy of anticancer drugs that have different molecular structures and mechanisms of action and is one of the primary causes of therapeutic failure. There have been successes in the development of cancer nanomedicine to overcome MDR; however, relatively few of these formulations have been approved by the United States Food and Drug Administration for the treatment of cancer. This is primarily due to the paucity of knowledge about nanotechnology and the fundamental biology of cancer cells. Here, we discuss the advances, types of nanomedicines, and the challenges regarding the translation of to results and their relevance to effective therapies.

Keywords

drug delivery systems enhanced permeability and retention effect multidrug resistance nanoformulations nanotechnology

References

  1. Nat Nanotechnol. 2010 Apr;5(4):271-4 [PMID: 20208548]
  2. Adv Drug Deliv Rev. 2014 Feb;66:110-6 [PMID: 24384374]
  3. Angew Chem Int Ed Engl. 2013 Jun 24;52(26):6580-9 [PMID: 23670869]
  4. J Control Release. 2022 May;345:572-585 [PMID: 35346766]
  5. Molecules. 2015 Dec 17;20(12):22578-620 [PMID: 26694341]
  6. Int J Nanomedicine. 2014 May 16;9:2399-407 [PMID: 24876773]
  7. Cancer Res. 2014 Dec 1;74(23):7003-13 [PMID: 25273092]
  8. Ann Oncol. 2011 Feb;22(2):438-43 [PMID: 20688844]
  9. Nutr Rev. 1998 Nov;56(11):317-33 [PMID: 9838798]
  10. Adv Mater. 2011 Mar 25;23(12):H79-83 [PMID: 21433105]
  11. Nat Nanotechnol. 2013 Feb;8(2):137-43 [PMID: 23334168]
  12. Biotechnol Annu Rev. 2001;7:59-85 [PMID: 11686049]
  13. Am J Clin Nutr. 2004 May;79(5):727-47 [PMID: 15113710]
  14. J Biol Inorg Chem. 2018 May;23(3):331-345 [PMID: 29453558]
  15. Int J Mol Sci. 2018 Jun 09;19(6): [PMID: 29890756]
  16. Int J Mol Sci. 2020 Jun 21;21(12): [PMID: 32575884]
  17. Expert Opin Drug Metab Toxicol. 2016;12(3):281-9 [PMID: 26799671]
  18. Mater Sci Eng C Mater Biol Appl. 2014 Jan 1;34:158-67 [PMID: 24268245]
  19. J Biomed Nanotechnol. 2020 Jan 1;16(1):111-124 [PMID: 31996290]
  20. Clin Cancer Res. 2011 Sep 1;17(17):5695-704 [PMID: 21791632]
  21. Pharmacol Res. 2007 Mar;55(3):224-36 [PMID: 17317210]
  22. Cancers (Basel). 2021 Aug 25;13(17): [PMID: 34503095]
  23. Int J Pharm. 2007 Aug 1;340(1-2):163-72 [PMID: 17482779]
  24. Theranostics. 2020 Jan 1;10(3):1319-1331 [PMID: 31938067]
  25. Ann Oncol. 2003 Sep;14(9):1430-7 [PMID: 12954584]
  26. Anticancer Agents Med Chem. 2018;18(2):302-311 [PMID: 28901265]
  27. Int J Nanomedicine. 2018 Dec 10;13:8411-8427 [PMID: 30587968]
  28. J Control Release. 2016 Oct 28;240:24-37 [PMID: 26458789]
  29. Adv Drug Deliv Rev. 2013 Nov;65(13-14):1699-715 [PMID: 23611952]
  30. Biochem Pharmacol. 1992 Aug 4;44(3):509-17 [PMID: 1354963]
  31. Nutrients. 2021 Feb 19;13(2): [PMID: 33669729]
  32. J Control Release. 2021 Apr 10;332:127-147 [PMID: 33609621]
  33. J Nat Prod. 2020 Mar 27;83(3):770-803 [PMID: 32162523]
  34. Nanoscale. 2011 Apr;3(4):1558-67 [PMID: 21283869]
  35. Biomed Mater. 2021 Mar 08;16(4): [PMID: 33621207]
  36. Arch Ophthalmol. 1987 Mar;105(3):400-3 [PMID: 3827719]
  37. Nanoscale. 2019 May 16;11(19):9661-9678 [PMID: 31065660]
  38. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2017 Sep;9(5): [PMID: 28198148]
  39. Proc Natl Acad Sci U S A. 2008 Aug 19;105(33):11613-8 [PMID: 18697944]
  40. Drug Discov Today. 2006 Sep;11(17-18):812-8 [PMID: 16935749]
  41. Ann Biomed Eng. 2013 Jan;41(1):68-77 [PMID: 22855118]
  42. Mol Pharm. 2019 Jan 7;16(1):1-23 [PMID: 30452861]
  43. J Agric Food Chem. 2001 Jan;49(1):14-20 [PMID: 11170553]
  44. Biochimie. 2016 Sep-Oct;128-129:99-112 [PMID: 27436182]
  45. Cancers (Basel). 2022 Dec 28;15(1): [PMID: 36612178]
  46. Colloids Surf B Biointerfaces. 2021 Aug;204:111773 [PMID: 33933878]
  47. Angew Chem Int Ed Engl. 2016 Mar 1;55(10):3309-12 [PMID: 26846161]
  48. Food Chem. 2021 Sep 1;355:129635 [PMID: 33780798]
  49. Molecules. 2020 Sep 29;25(19): [PMID: 33003351]
  50. J Nanobiotechnology. 2018 Sep 19;16(1):71 [PMID: 30231877]
  51. Front Bioeng Biotechnol. 2019 Oct 22;7:287 [PMID: 31696113]
  52. Chem Rev. 2015 Oct 14;115(19):10938-66 [PMID: 26010257]
  53. J Adv Pharm Technol Res. 2018 Jan-Mar;9(1):2-8 [PMID: 29441317]
  54. J Control Release. 2019 Dec 28;316:359-380 [PMID: 31682912]
  55. Langmuir. 2020 Dec 1;36(47):14268-14275 [PMID: 33201705]
  56. Carcinogenesis. 2010 Apr;31(4):634-42 [PMID: 20044584]
  57. Int J Biol Macromol. 2021 Dec 15;193(Pt A):528-540 [PMID: 34655592]
  58. Nat Nanotechnol. 2008 Mar;3(3):151-7 [PMID: 18654487]
  59. Biomaterials. 2010 May;31(13):3694-706 [PMID: 20144478]
  60. Molecules. 2021 Sep 29;26(19): [PMID: 34641447]
  61. Int J Mol Sci. 2020 Nov 27;21(23): [PMID: 33261095]
  62. Nanomedicine. 2021 Jul;35:102307 [PMID: 32987192]
  63. Hepatology. 2005 Jun;41(6):1211-9 [PMID: 15915465]
  64. Nano Lett. 2012 Jul 11;12(7):3587-91 [PMID: 22716029]
  65. Curr Opin Gastroenterol. 2006 Mar;22(2):165-70 [PMID: 16462174]
  66. Drug Deliv. 2004 Jan-Feb;11(1):33-9 [PMID: 15168789]
  67. Biomaterials. 2008 May;29(13):2104-12 [PMID: 18276001]
  68. Nanomedicine. 2013 Jul;9(5):675-85 [PMID: 23219878]
  69. Cancer Res. 2011 Mar 15;71(6):2250-9 [PMID: 21406401]
  70. Chem Soc Rev. 2012 Apr 7;41(7):2780-99 [PMID: 22086677]
  71. IET Nanobiotechnol. 2017 Apr;11(3):261-267 [PMID: 28476983]
  72. Curr Med Chem. 2018;25(25):2938-2953 [PMID: 28292234]
  73. Nat Med. 2013 Nov;19(11):1423-37 [PMID: 24202395]
  74. Recent Pat Nanotechnol. 2015;9(1):51-60 [PMID: 25986229]
  75. Biochemistry. 1987 Jan 13;26(1):17-29 [PMID: 3828297]
  76. J Agric Food Chem. 2001 Mar;49(3):1270-6 [PMID: 11312849]
  77. Nanoscale. 2014 Oct 7;6(19):11439-50 [PMID: 25154771]
  78. BMC Cancer. 2009 Nov 16;9:399 [PMID: 19917123]
  79. Int J Nanomedicine. 2012;7:151-62 [PMID: 22275831]
  80. Drug Dev Ind Pharm. 2014 Feb;40(2):260-5 [PMID: 23356860]
  81. Int J Pharm. 2015 Jul 5;488(1-2):44-58 [PMID: 25899286]
  82. J Control Release. 2009 Jul 1;137(1):78-86 [PMID: 19285109]
  83. Biomaterials. 2010 Nov;31(32):8393-401 [PMID: 20688391]
  84. Methods Mol Biol. 2020;2059:1-54 [PMID: 31435914]
  85. Methods Mol Biol. 2010;624:25-37 [PMID: 20217587]
  86. Pharmaceutics. 2021 May 12;13(5): [PMID: 34066092]
  87. Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4607-12 [PMID: 9539785]
  88. Postepy Hig Med Dosw. 2001;55(1):17-36 [PMID: 11355530]
  89. AAPS PharmSciTech. 2010 Sep;11(3):1206-11 [PMID: 20680708]
  90. Int J Pharm. 2011 Sep 30;417(1-2):101-11 [PMID: 21256941]
  91. Pharmaceutics. 2022 Feb 10;14(2): [PMID: 35214127]
  92. Acta Physiol (Oxf). 2008 Dec;194(4):335-9 [PMID: 18729843]
  93. Nanomaterials (Basel). 2021 Aug 10;11(8): [PMID: 34443864]
  94. J Control Release. 2023 Aug;360:591-612 [PMID: 37422123]
  95. J Control Release. 2018 Jan 28;270:290-303 [PMID: 29269142]
  96. Chem Soc Rev. 2012 Apr 7;41(7):2545-61 [PMID: 22334259]
  97. Mol Ther. 2010 Sep;18(9):1650-6 [PMID: 20606648]
  98. Int J Pharm. 2021 May 15;601:120571 [PMID: 33812967]
  99. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2016 Sep;8(5):678-95 [PMID: 26749497]
  100. Am J Clin Nutr. 2005 Jan;81(1 Suppl):230S-242S [PMID: 15640486]
  101. Mater Sci Eng C Mater Biol Appl. 2020 Jan;106:110302 [PMID: 31753337]
  102. Nat Rev Cancer. 2017 Jan;17(1):20-37 [PMID: 27834398]
  103. Am J Clin Nutr. 2000 Dec;72(6):1424-35 [PMID: 11101467]
  104. Food Funct. 2021 Aug 2;12(15):6664-6681 [PMID: 34152346]
  105. Front Pharmacol. 2019 Mar 05;10:152 [PMID: 30890933]
  106. Clin Cancer Res. 2010 Dec 15;16(24):6139-49 [PMID: 20876255]
  107. Nat Biotechnol. 2013 Jul;31(7):638-46 [PMID: 23792630]
  108. J Pharm Sci. 2001 Dec;90(12):1927-36 [PMID: 11745751]
  109. J Drug Target. 2005 Jan;13(1):73-80 [PMID: 15848957]
  110. Cancers (Basel). 2019 Nov 25;11(12): [PMID: 31769416]
  111. Nanomedicine. 2008 Mar;4(1):49-56 [PMID: 18249155]
  112. ACS Nano. 2010 Mar 23;4(3):1671-9 [PMID: 20166699]
  113. J Nanosci Nanotechnol. 2014 Jun;14(6):4377-82 [PMID: 24738399]
  114. J Am Chem Soc. 2012 Apr 25;134(16):6948-51 [PMID: 22475086]
  115. Int J Pharm. 2006 Jun 6;315(1-2):148-57 [PMID: 16616818]
  116. Expert Opin Drug Deliv. 2006 Jan;3(1):139-62 [PMID: 16370946]
  117. Nat Nanotechnol. 2012 Apr 08;7(6):383-8 [PMID: 22484912]
  118. Nano Lett. 2008 Sep;8(9):2906-12 [PMID: 18656990]
  119. Proc Natl Acad Sci U S A. 2012 Oct 2;109(40):16288-93 [PMID: 22991470]
  120. ACS Appl Mater Interfaces. 2022 Apr 6;14(13):14916-14927 [PMID: 35316026]
  121. Eur J Pharm Biopharm. 2008 Sep;70(1):51-7 [PMID: 18583114]
  122. Molecules. 2021 Oct 22;26(21): [PMID: 34770796]
  123. Nano Lett. 2008 Aug;8(8):2559-63 [PMID: 18611058]
  124. Colloids Surf B Biointerfaces. 2021 Feb;198:111455 [PMID: 33243547]
  125. J Biomater Appl. 2011 Feb;25(6):619-39 [PMID: 20207782]
  126. Nutr Res. 2011 Feb;31(2):77-87 [PMID: 21419311]
  127. Biochim Biophys Acta. 2016 Jan;1860(1 Pt A):108-19 [PMID: 26391840]
  128. J Control Release. 2014 Sep 28;190:485-99 [PMID: 24984011]
  129. J Agric Food Chem. 1999 Jul;47(7):2719-23 [PMID: 10552552]
  130. ACS Nano. 2011 May 24;5(5):3679-92 [PMID: 21462992]
  131. Nutrients. 2014 Dec 22;6(12):6020-47 [PMID: 25533011]
  132. Cancer. 2005 Aug 15;104(4):682-91 [PMID: 15986399]
  133. J Mol Biol. 1964 May;8:660-8 [PMID: 14187392]
  134. J Nanosci Nanotechnol. 2018 Aug 1;18(8):5306-5313 [PMID: 29458581]
  135. Adv Mater. 2022 Jan;34(1):e2100245 [PMID: 34613635]
  136. Nanomaterials (Basel). 2021 Sep 24;11(10): [PMID: 34684925]
  137. Macromol Biosci. 2014 Sep;14(9):1337-45 [PMID: 24933015]
  138. J Clin Oncol. 2014 Dec 20;32(36):4141-8 [PMID: 25403217]
  139. Nanomedicine. 2010 Apr;6(2):382-90 [PMID: 19836468]
  140. Int J Pharm. 2006 Jan 3;307(1):93-102 [PMID: 16303268]
  141. Oncotarget. 2016 Feb 2;7(5):5877-91 [PMID: 26716507]
  142. ACS Nano. 2016 Mar 22;10(3):3723-37 [PMID: 26882007]
  143. Eur J Pharm Biopharm. 2013 Feb;83(2):266-74 [PMID: 23089310]
  144. Chem Soc Rev. 2017 Oct 2;46(19):5771-5804 [PMID: 28654103]
  145. J Control Release. 2008 Aug 25;130(1):86-94 [PMID: 18614254]
  146. Adv Cancer Res. 2018;139:163-184 [PMID: 29941104]
  147. Int J Biol Macromol. 2016 Oct;91:703-9 [PMID: 27177461]
  148. AAPS PharmSciTech. 2015 Dec;16(6):1409-17 [PMID: 25986595]
  149. Int J Oncol. 2019 Feb;54(2):407-419 [PMID: 30570109]
  150. Int J Nanomedicine. 2006;1(3):297-315 [PMID: 17717971]
  151. Chem Rev. 2011 Sep 14;111(9):5610-37 [PMID: 21688848]
  152. J Agric Food Chem. 2019 Jan 23;67(3):887-894 [PMID: 30608682]
  153. Int J Pharm. 2020 Nov 30;590:119912 [PMID: 32971178]
  154. Acc Chem Res. 2019 Sep 17;52(9):2445-2461 [PMID: 31424909]
  155. Nano Lett. 2007 Dec;7(12):3759-65 [PMID: 17979310]
  156. J Pharm Bioallied Sci. 2010 Oct;2(4):282-9 [PMID: 21180459]
  157. Biochim Biophys Acta Gen Subj. 2023 Sep;1867(9):130396 [PMID: 37271407]
  158. J Control Release. 2005 Dec 5;109(1-3):169-88 [PMID: 16289422]
  159. Anticancer Drugs. 1996 Jun;7(4):461-8 [PMID: 8826614]
  160. Sci Rep. 2019 Oct 4;9(1):14351 [PMID: 31586116]
  161. J Liposome Res. 2010 Sep;20(3):228-43 [PMID: 19899957]
  162. J Pharm Sci. 2014 Aug;103(8):2315-22 [PMID: 24914015]
  163. Molecules. 2015 Dec 22;21(1):E4 [PMID: 26791291]
  164. Int J Mol Sci. 2019 Feb 17;20(4): [PMID: 30781560]
  165. Anticancer Agents Med Chem. 2014;14(10):1332-42 [PMID: 24975033]
  166. Biophys J. 1997 Nov;73(5):2615-29 [PMID: 9370456]
  167. Appl Biochem Biotechnol. 2014 May;173(1):1-29 [PMID: 24622849]
  168. Molecules. 2019 Nov 28;24(23): [PMID: 31795265]
  169. Science. 2013 Feb 22;339(6122):971-5 [PMID: 23430657]
  170. Nutr Rev. 2008 Aug;66(8):445-54 [PMID: 18667005]
  171. Cancer Res. 2013 Aug 1;73(15):4862-71 [PMID: 23907638]
  172. RSC Adv. 2021 May 5;11(27):16619-16632 [PMID: 35479146]
  173. Curr Pharm Des. 2010 Jan;16(1):114-34 [PMID: 20214622]
  174. Nano Lett. 2016 Jan 13;16(1):177-81 [PMID: 26654461]
  175. Adv Mater. 2008 May 5;20(9):1630-1635 [PMID: 21687830]
  176. Nat Med. 2011 Oct 11;17(10):1217-20 [PMID: 21989013]
  177. RSC Adv. 2021 Sep 13;11(48):30343-30352 [PMID: 35480249]
  178. Int J Pharm. 2010 Jun 30;393(1-2):176-84 [PMID: 20381598]
  179. Nanotoxicology. 2012 Feb;6(1):36-46 [PMID: 21309618]
  180. J Microencapsul. 2017 Jun;34(4):408-415 [PMID: 28590788]
  181. Annu Rev Immunol. 2021 Apr 26;39:583-609 [PMID: 33637019]
  182. Eur J Pharm Biopharm. 2009 Feb;71(2):251-6 [PMID: 18805484]
  183. J Control Release. 2004 Dec 10;100(3):451-5 [PMID: 15567509]
  184. Drug Discov Today. 2021 May;26(5):1284-1292 [PMID: 33549529]
  185. Nat Nanotechnol. 2012 Dec;7(12):779-86 [PMID: 23212421]
  186. Colloids Surf B Biointerfaces. 2015 Nov 1;135:291-308 [PMID: 26263217]
  187. Pharmacol Res. 2011 Jan;63(1):51-8 [PMID: 21035550]
  188. Nanomedicine (Lond). 2015;10(8):1315-26 [PMID: 25955125]
  189. Nature. 2015 Oct 1;526(7571):118-21 [PMID: 26374997]
  190. J Liposome Res. 2005;15(1-2):49-58 [PMID: 16194927]
  191. Antioxidants (Basel). 2019 Oct 08;8(10): [PMID: 31597312]
  192. J Liposome Res. 2017 Sep;27(3):173-179 [PMID: 28967274]
  193. Int J Mol Sci. 2021 Dec 02;22(23): [PMID: 34884848]
  194. Drug Discov Today. 2015 May;20(5):595-601 [PMID: 25543008]
  195. Mol Biomed. 2021 Sep 10;2(1):27 [PMID: 35006446]
  196. Int J Biol Macromol. 2021 May 15;179:125-135 [PMID: 33667554]
  197. Sci Transl Med. 2013 Nov 27;5(213):213ra167 [PMID: 24285486]
  198. Oncol Rep. 2017 Aug;38(2):611-624 [PMID: 28627697]
  199. Crit Rev Microbiol. 2016;42(2):173-80 [PMID: 24937409]
  200. Eur J Clin Nutr. 2010 Nov;64 Suppl 3:S112-20 [PMID: 21045839]
  201. Nat Nanotechnol. 2013 Jan;8(1):61-8 [PMID: 23241654]
  202. ACS Nano. 2014 Mar 25;8(3):2439-55 [PMID: 24517450]
  203. J Control Release. 2011 Oct 30;155(2):119-27 [PMID: 21699934]
  204. Adv Drug Deliv Rev. 2020;154-155:102-122 [PMID: 32650041]
  205. Pharmaceutics. 2016 Mar 28;8(2): [PMID: 27043614]
  206. Acc Chem Res. 2008 Dec;41(12):1587-95 [PMID: 18570442]
  207. Nat Commun. 2013;4:2718 [PMID: 24177351]
  208. Mini Rev Med Chem. 2020;20(13):1258-1271 [PMID: 32386491]
  209. J Control Release. 2012 Jan 30;157(2):168-82 [PMID: 21839127]
  210. Evid Based Complement Alternat Med. 2011;2011:591356 [PMID: 21792362]
  211. Langmuir. 2020 Jan 21;36(2):600-608 [PMID: 31885276]
  212. J Control Release. 2021 Apr 10;332:312-336 [PMID: 33652113]
  213. Biomaterials. 2009 Apr;30(12):2231-40 [PMID: 19167749]
  214. Biomaterials. 2013 Jan;34(4):1213-22 [PMID: 23102622]
  215. J Am Chem Soc. 2012 Feb 1;134(4):2139-47 [PMID: 22191645]
  216. Biochemistry. 1985 Jun 4;24(12):2833-42 [PMID: 2990532]
  217. J Clin Oncol. 2008 Jun 1;26(16):2674-82 [PMID: 18509179]
  218. Nat Rev Cancer. 2009 Sep;9(9):665-74 [PMID: 19693095]
  219. Cancer Cell. 2005 Jun;7(6):513-20 [PMID: 15950901]
  220. Int J Pharm. 2007 Feb 22;331(1):1-10 [PMID: 17110063]
  221. J Sep Sci. 2007 Dec;30(18):3268-95 [PMID: 18069740]
  222. J Nanosci Nanotechnol. 2019 Jul 1;19(7):3720-3733 [PMID: 30764928]
  223. Lab Chip. 2009 Jul 21;9(14):2026-35 [PMID: 19568671]
  224. Proc Natl Acad Sci U S A. 1978 Sep;75(9):4194-8 [PMID: 279908]
  225. Int J Biol Macromol. 2021 Nov 1;190:520-532 [PMID: 34480908]
  226. ACS Nano. 2009 Jan 27;3(1):16-20 [PMID: 19206243]
  227. J Drug Target. 2004;12(7):461-71 [PMID: 15621671]
  228. Drug Discov Today. 2019 Feb;24(2):462-491 [PMID: 30121330]
  229. Nature. 2004 Feb 19;427(6976):695 [PMID: 14973470]
  230. Br J Radiol. 2018 Nov;91(1091):20170926 [PMID: 29947266]
  231. Nutr Res Rev. 2000 Jun;13(1):79-106 [PMID: 19087434]
  232. Sci Transl Med. 2012 Apr 4;4(128):128ra39 [PMID: 22491949]
  233. Pharmaceutics. 2021 Aug 19;13(8): [PMID: 34452256]
  234. Toxicol Lett. 2012 Nov 30;215(2):119-25 [PMID: 23046612]
  235. Biochim Biophys Acta. 2001 Apr 2;1511(2):397-411 [PMID: 11286983]
  236. Nat Rev Drug Discov. 2015 Dec;14(12):843-56 [PMID: 26567702]
  237. Int J Mol Sci. 2021 Aug 05;22(16): [PMID: 34445120]
  238. Biomater Res. 2019 Nov 21;23:20 [PMID: 31832232]
  239. Biomaterials. 2010 Jun;31(16):4583-91 [PMID: 20219241]
  240. Int J Nanomedicine. 2017 May 24;12:3941-3965 [PMID: 28579779]
  241. Nat Mater. 2013 Nov;12(11):967-77 [PMID: 24150415]
  242. Nat Rev Clin Oncol. 2010 Nov;7(11):653-64 [PMID: 20838415]
  243. Adv Drug Deliv Rev. 2014 Feb;66:42-57 [PMID: 24060923]
  244. Nanoscale Res Lett. 2013 Feb 22;8(1):102 [PMID: 23432972]
  245. Small. 2023 Aug;19(32):e2300341 [PMID: 37029564]
  246. J Pharm Sci. 2021 Sep;110(9):3111-3117 [PMID: 33989679]
  247. FEBS J. 2013 Jan;280(1):28-45 [PMID: 23181775]
  248. Proc Natl Acad Sci U S A. 2014 Aug 5;111(31):11449-54 [PMID: 25049380]
  249. Oncogene. 2004 Apr 1;23(14):2507-22 [PMID: 14676829]
  250. Drug Deliv. 2016 Sep;23(7):2587-2595 [PMID: 26066393]
  251. Methods Mol Biol. 2017;1522:17-22 [PMID: 27837527]
  252. Colloids Surf B Biointerfaces. 2019 Jun 1;178:263-268 [PMID: 30877911]
  253. Eur J Pharm Sci. 1999 May;8(2):99-107 [PMID: 10210732]
  254. Science. 1994 Mar 18;263(5153):1600-3 [PMID: 8128245]
  255. J Liposome Res. 2011 Mar;21(1):70-80 [PMID: 20528623]
  256. Artif Cells Nanomed Biotechnol. 2018;46(sup3):S611-S620 [PMID: 30444132]
  257. Biomedicines. 2019 Jul 03;7(3): [PMID: 31277332]
  258. Bioimpacts. 2017;7(3):155-166 [PMID: 29159143]
  259. Adv Mater. 2012 Mar 22;24(12):1504-34 [PMID: 22378538]
  260. Int J Pharm. 2008 Feb 12;349(1-2):274-82 [PMID: 17870261]
  261. Proc Natl Acad Sci U S A. 2013 Sep 10;110(37):15127-32 [PMID: 23980155]
  262. Chem Soc Rev. 2012 Apr 7;41(7):2971-3010 [PMID: 22388185]
  263. J Control Release. 2021 Mar 10;331:416-433 [PMID: 33503486]
  264. Biomaterials. 2019 Mar;197:220-228 [PMID: 30669014]
  265. Biomaterials. 2009 Mar;30(7):1363-71 [PMID: 19100617]
  266. Chem Phys Lipids. 1986 Jun-Jul;40(2-4):333-45 [PMID: 3742676]
  267. J Drug Target. 2006 Jan;14(1):45-53 [PMID: 16603451]
  268. Chem Soc Rev. 2012 Apr 7;41(7):2740-79 [PMID: 22109657]
  269. Biomaterials. 2010 Mar;31(9):2646-54 [PMID: 20036420]
  270. Nanotechnology. 2021 May 17;32(32): [PMID: 33910182]
  271. ACS Nano. 2010 Jul 27;4(7):3689-96 [PMID: 20550178]
  272. Molecules. 2010 Oct 21;15(10):7313-52 [PMID: 20966876]
  273. J Am Chem Soc. 2005 Jul 20;127(28):10096-100 [PMID: 16011375]
  274. J Control Release. 2016 Aug 10;235:337-351 [PMID: 27297779]
  275. Cancer Lett. 1992 Jul 31;65(1):51-4 [PMID: 1511409]
  276. Oncotarget. 2021 Mar 02;12(5):422-439 [PMID: 33747358]
  277. J Clin Oncol. 2009 Jun 1;27(16):2712-25 [PMID: 19414669]
  278. Molecules. 2021 Sep 26;26(19): [PMID: 34641367]
  279. Science. 2002 Jun 28;296(5577):2404-7 [PMID: 12089446]
  280. J Clin Oncol. 2001 Jun 15;19(12):2975-82 [PMID: 11408492]
  281. Colloids Surf B Biointerfaces. 2019 Mar 1;175:248-255 [PMID: 30540972]
  282. Angew Chem Int Ed Engl. 2011 Nov 25;50(48):11417-20 [PMID: 22113800]
  283. Acta Biomater. 2015 Oct;25:268-83 [PMID: 26219859]
  284. J Mater Chem B. 2014 Mar 14;2(10):1327-1334 [PMID: 32261447]
  285. Proc Natl Acad Sci U S A. 2008 Jul 8;105(27):9343-8 [PMID: 18607000]
  286. Carcinogenesis. 1998 Apr;19(4):611-6 [PMID: 9600345]
  287. Int J Nanomedicine. 2010 Sep 20;5:669-77 [PMID: 20957218]
  288. Biomater Sci. 2014 Sep 29;2(9):1210-1221 [PMID: 32481892]
  289. ACS Appl Mater Interfaces. 2018 Aug 1;10(30):25006-25016 [PMID: 29781607]
  290. Nat Biotechnol. 2013 Jul;31(7):653-8 [PMID: 23792629]
  291. Biomacromolecules. 2015 Apr 13;16(4):1311-21 [PMID: 25794196]
  292. Adv Drug Deliv Rev. 2017 Jun 1;115:57-81 [PMID: 28412324]
  293. Proc Natl Acad Sci U S A. 2013 Nov 19;110(47):19048-53 [PMID: 24191048]
  294. Bioconjug Chem. 2014 Jul 16;25(7):1223-32 [PMID: 24873191]
  295. Int J Pharm. 2019 Jun 30;565:447-457 [PMID: 31071418]
  296. Recent Adv Drug Deliv Formul. 2021;15(1):59-74 [PMID: 34602031]
  297. Annu Rev Biomed Eng. 2012;14:1-16 [PMID: 22524388]
  298. Int J Nanomedicine. 2009;4:99-105 [PMID: 19516888]
  299. Biomater Sci. 2019 Sep 1;7(9):3866-3875 [PMID: 31309204]
  300. Nutr Rev. 2013 Sep;71(9):585-99 [PMID: 24032363]
  301. Nat Mater. 2009 Jul;8(7):543-57 [PMID: 19525947]
  302. Mol Membr Biol. 2010 Oct;27(7):232-46 [PMID: 20929339]
  303. Proc Natl Acad Sci U S A. 2011 Feb 8;108(6):2426-31 [PMID: 21245339]
  304. Adv Drug Deliv Rev. 2014 Feb;66:2-25 [PMID: 24270007]
  305. Science. 2010 Jun 25;328(5986):1662-8 [PMID: 20576885]
  306. Nat Commun. 2015 Oct 27;6:8692 [PMID: 26503691]
  307. BMJ Open. 2021 Nov 30;11(11):e050725 [PMID: 34848513]
  308. Angew Chem Int Ed Engl. 2010 Aug 23;49(36):6288-308 [PMID: 20648499]
  309. Biomaterials. 2011 Apr;32(11):2894-906 [PMID: 21256584]
  310. Artif Cells Nanomed Biotechnol. 2016;44(1):381-91 [PMID: 25222036]
  311. Sci Transl Med. 2015 Nov 18;7(314):314ra183 [PMID: 26582898]
  312. Theranostics. 2020 Jan 1;10(1):371-383 [PMID: 31903126]
  313. Int J Pharm. 2013 Mar 10;445(1-2):117-24 [PMID: 23384729]
  314. ACS Nano. 2010 Feb 23;4(2):625-31 [PMID: 20121215]
  315. Proc Natl Acad Sci U S A. 2007 Feb 13;104(7):2050-5 [PMID: 17267609]
  316. Biomaterials. 2013 Dec;34(37):9602-14 [PMID: 24021757]
  317. Nano Lett. 2006 Apr;6(4):662-8 [PMID: 16608261]
  318. Nanoscale. 2012 Jan 7;4(1):239-50 [PMID: 22080352]
  319. Drug Des Devel Ther. 2020 Aug 12;14:3271-3289 [PMID: 32848366]
Journal Article Review

Word Cloud

Created with Highcharts 10.0.0cancernanotechnologyovercomeresistancenanomedicinedefinedcanMDRcellsdeliverysystemsdrugCancerapplicationnanomaterialsformulationtherapeuticsimpedimentsrestrictionstraditionalchemotherapeuticsMultidrugdecreaseabrogationefficacyanticancerdrugsdifferentmolecularstructuresmechanismsactiononeprimarycausestherapeuticfailuresuccessesdevelopmenthoweverrelativelyformulationsapprovedUnitedStatesFoodDrugAdministrationtreatmentprimarilyduepaucityknowledgefundamentalbiologydiscussadvancestypesnanomedicineschallengesregardingtranslationresultsrelevanceeffectivetherapiesNanotechnology-basedenhancedpermeabilityretentioneffectmultidrugnanoformulations

Similar Articles

Cited By